Fourth Quarter 2020 Analyst Presentation Growth Since Going Public

From Continuing Operations

(in millions, except per share data)

Net Sales Operating Income Operating Margin Net Income Diluted EPS

* Average annual increase

1995

GAAP Basis 2020

CAGR

  • $ 583.6

  • $ (2.5)

    $ 10,119.1 $ 535.3

    -0.43%

    5.29%

  • $ (11.0) $ 402.8

  • $ (0.21) $ 2.81

Special Management Compensation Costs 1995 2020

Reconciling ItemsRestructuring Costs 1995 2020

12.09%

  • $ -$ $

- -$

-

  • $ -

    n/a (1) 572 bp

    $

    20.8

  • $ 32.1

    n/a (1)

    $ $

    19.6 0.37

    $ $

    - -

  • $ 24.1

    n/a (1)

  • $ 0.17

(1) In 1995, Operating Income, Net Income and Diluted EPS were negative, and CAGR amounts cannot be calculated. Using 1996 as a base year the CAGR for Operating Income, Net Income and Diluted EPS was 15.08%, 17.15%, and 14.23%, respectively. For 1996, there we no reconciling items on a GAAP to Non-GAAP basis.

Net Gain on Sale of

Investments 1995 2020

1995

Non-GAAP 2020

CAGR

$ 583.6 $ 10,119.1 12.1%

$ 18.3 $ 567.4 14.7%

3.13%

5.61%

10 bps*

$ $

(1.6) $ 8.6 $ 425.3 16.9%

(0.01) $ 0.16 $ 2.97 12.4%

Fourth Quarter 2020 Analyst Presentation Full Year 2020 Financial Highlights

From Continuing Operations

(in millions, except per share data)

Net Sales Operating Income Operating Margin Net Income Diluted EPS

2019

GAAP Basis 2020

Growth

  • $ 9,985.8

  • $ 718.3 7.19%

    $ 10,119.1 $ 535.3

    5.29%

  • $ 700.7 $ 402.8

  • $ 4.69 $ 2.81

Restructuring Costs 2019 2020

Reconciling ItemsNet Gain on Sale of Equity Investments 2019 2020

1.3%

-25.5%

$ $ $

14.7

  • $ 32.1

    (190) bp

    -42.5%

    -40.1%

    11.0 0.07

  • $ 24.1

  • $ 0.17

$ (186.8) $ (1.6) $ (1.25) $ (0.01)

Tax Credit Related to Animal Health Spin-off

2019

2020

Total Reconciling Items 2019 2020

  • $ -

    • $ -

  • $ 14.7

    $

    $ (1.3) $ $ (0.01) $

    - -

  • $ (177.1) $

  • $ (1.19) $

2019

Non-GAAP 2020

Growth

$ $

  • 9,985.8 $ 10,119.1

    32.1

  • 733.0 $ 567.4

  • 7.34% 5.61%

1.3% -22.6% (173) bp

22.5 0.16

$ 523.6 $ 425.3 -18.8%

$ 3.51 $ 2.97 -15.4%

Henry Schein, Inc.

Fourth Quarter 2020 Analyst Presentation Q4 2020 - Financial Highlights

From Continuing Operations

(in millions, except per share data)

Reconciling Items

2019 Restructuring Credits and 2020

Q4 2019

GAAP Basis

Q4 2020

Growth

Net Sales Operating Income Operating Margin Net Income Diluted EPS

  • $ 2,668.9 $

    • 3,165.7 18.6%

  • $ 196.3 $ 7.36%

    • 181.2 -7.7%

    • 5.72% (164) bp

    Restructuring Costs 2019

    Net Gain on Sale of Equity Investments

    Non-GAAP

    2020

    2019

    2020

    Q4 2019

    Q4 2020

    Growth

    • $ 2,668.9 $

      • 3,165.7 18.6%

        $

        (1.1) $ 4.4

  • $ 330.6 $

    141.9 0.99

    -57.1% -56.0%

    $ $

    (0.8) $ 3.3

  • $ 2.25 $

(0.01) $ 0.02

  • $ 195.3 $ 7.32%

    • 185.6 -5.0%

    • 5.86% (146) bp

      $ $

      (186.8) $ (1.27) $

      (1.6) (0.01)

  • $ 143.0 $

    • 143.6 0.4%

  • $ 0.97 $

  • 1.00 3.1%

Henry Schein, Inc.

Fourth Quarter 2020 Analyst Presentation Q4 2020 - Financial Highlights

From Continuing Operations

(in millions, except per share data)

Net Sales Operating Income Operating Margin

GAAP BasisQ4 2019

Q4 2020

Growth

  • $ 2,668.9 $

  • $ 196.3 $ 7.36%

  • 3,165.7 18.6%

  • 181.2 -7.7%

  • 5.72% (163) bp

Reconciling Items

2019 Restructuring Credits and 2020

Q4 2019 Q4 2020

Non-GAAPQ4 2019

Q4 2020

Growth

$

- (1.1)

$

- 4.4

  • $ 2,668.9 $

  • $ 195.3 $ 7.32%

  • 3,165.7 18.6%

  • 185.6 -5.0%

  • 5.86% (146) bp

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Henry Schein Inc. published this content on 17 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 February 2021 13:35:06 UTC.